Novo Nordisk’s ZEUS trial cut IL-6 by 76% in 6,376 patients but produced zero reduction in heart attacks, mirroring ...
Saroglitazar resolved MASH in 39% of patients, nearly triple the placebo rate, in Zydus’ Phase IIb EVIDENCES-X trial at AASLD 2026. Phase III still needed.
NASA names 8 firms to a $10B Moon Base cargo contract; Blue Origin wins $94M to carry the nuclear PROMISE rover to the lunar ...
Comet 11P/Tempel-Swift-LINEAR reaches perihelion on November 9, 2026 - its most geometrically favorable northern-sky ...
Viasat has won a $450 million Space Force contract to build the Mission Operations Center directing real-time data routing ...
The Sigma FP2 launches November 11 at $2,199, delivering 6K ProRes RAW HQ at 5,800 Mbps from the world’s smallest full-frame ...
Long March 12 launches its tenth Guowang mission from Hainan tonight at 3:25 PM ET. With only 230 of 12,992 planned ...
Stable coronary artery disease patients gain no survival benefit from stents or bypass surgery, a landmark 13-year trial ...
Stopping statins for primary prevention appears safe at two years for multimorbid adults 70 and older, but the STREAM trial’s ...
Stroke prevention blood pressure research reaches a landmark turn: the OPTIMAL-Stroke trial, the largest RCT ever in ischemic stroke and TIA survivors, found that a systolic target below 120 mm Hg ...
Precision BioSciences’ gene editing therapy PBGENE-HBV eliminated hepatitis B’s cccDNA viral reservoir in every evaluable ...
A five-year RCT of PulsePoint, the CPR alert app in nearly 6,000 communities, found no statistically significant benefit from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results